MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Ixazomib (Primary) ; Pevonedistat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2023 Status changed from active, no longer recruiting to completed.
- 23 Feb 2023 Planned End Date changed from 23 Apr 2023 to 22 Feb 2024.
- 12 Apr 2022 Planned End Date changed from 23 Apr 2022 to 23 Apr 2023.